Our findings that warfarin, the vitamin K antagonist, and rivaroxaban, the factor Xa inhibitor, capable of reducing thrombin generation, suppressed the TMα-induced prevention of CIPN (see Fig. 4) caution the possibility that TMα may not be effective as a prophylactic agent for CIPN in cancer patients undergoing anticoagulant therapy for thrombotic diseases, unless the use of anticoagulants is temporarily stopped. This evidence concerns the gene F10 and cancer.